Similar articles

• Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.

  Vannasaeng S, Ploybutr S, Nitiyanant W, Peerapatdit T, Vichayanrat A. Vannasaeng S, et al. J Med Assoc Thai. 1995 Nov;78(11):578-85. J Med Assoc Thai. 1995. PMID: 8576667 Clinical Trial.
• [Inhibition of intestinal alpha glucosidases in the therapy of diabetes mellitus].

  Fölsch UR, Lembcke B. Fölsch UR, et al. Internist (Berl). 1991 Dec;32(12):699-707. Internist (Berl). 1991. PMID: 1823561 Review. German. No abstract available.
• Clinical experience with acarbose as first line therapy in NIDDM.

  Fölsch UR. Fölsch UR. Clin Invest Med. 1995 Aug;18(4):312-7. Clin Invest Med. 1995. PMID: 8549018 Review.
• [Acarbose in the treatment of non-insulin-dependent diabetes mellitus; a new principle].

  Drent ML, van der Veen EA. Drent ML, et al. Ned Tijdschr Geneeskd. 1992 Feb 15;136(7):308-10. Ned Tijdschr Geneeskd. 1992. PMID: 1538796 Review. Dutch. No abstract available.
• [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].

  García de los Ríos M, Mujica V, Muñoz S, Durruty P, Larenas G, López MI, Kuzmanic A, Pérez J, Flaskamp R, Cumsille F. García de los Ríos M, et al. Rev Med Chil. 1997 Aug;125(8):856-62. Rev Med Chil. 1997. PMID: 9580485 Clinical Trial. Spanish.